Please enter the email address you used to register, then we will send you a link to choose a new password
SGMT: 94% | Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH
RVSN: 142% | Rail Vision Says Its Main Line System Has Successfully Obtained Formal Certifications For Critical European Union Railway Standards
CHRS: 33% | Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal
Posted In: CHRS RVSN SGMT